|
Brain
RTOG R0625 Protocol ( 5/19/2009) A Randomized
Phase II Trial of Bevacizumab with Irinotecan or
Bevacizumab with Temozolomide in Recurrent
Glioblastoma
NCCTG RTOG 0525
Protocol
(closure 6/13/2008) Phase II Trial
Comparing Conventional Adjuvant Temozolomide
with Dose-Intensive Temozolomide in Patients
with Newly Diagnosed Glioblastoma
Breast
CTSU CALGB 40302 Protocol (Closure
07/14/10) Endocrine
Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors:
A Randomized, Double-Blinded, Placebo-controlled Phase III Trial of Fulvestrant
with or without Lapatinib for Postmenopausal Women with Hormone Receptor
Positive Advanced Breast Cancer
SWOG
S0226
Protocol (7/1/09) Phase III Randomized Trial of Anastrozole vs. Anastrozole
and Fulvestrant as First-Line Therapy for Post Menopausal Women with Metastatic Breast
Cancer
SWOG JMA.17R Protocol ( 5/8/09)A Double Blind Randomization To Letrozole or Placebo For
Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of
Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen
(including those in the MA.17 study)
NSABP B-36
Protocol
A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil,
Epirubicin and Cyclophosphamide to Four Cycles of Adriamycin and
Cyclophosphamide, With or Without Celecoxib, in
patients with Node-Negative Breast Cancer
CTSU MA.27
Protocol (closure
7/31/08)
A Randomized Phase III Trial of Exemestane vs Anastrozole in Postmenopausal
Women with Receptor Positive Primary Breast Cancer
CTSU MA.27B
Protocol
(closure 5/30/08)
The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone
Mineral Density in Postmenopausal Women with Primary Breast Cancer
CTSU N0434 (MA.27D)
Protocol
Association of Breast Density Changes, Plasma Hormone Changes and Breast Cancer
Recurrence (Companion MA.27D)
NSABP B-30
Protocol
A Three-Arm
Randomized Trial To Compare Adjuvant Adriamycin
And Cyclophosphamide Followed By Taxotere (AC →
T); Adriamycin And Taxotere (AT); And Adriamycin,
Taxotere, And Cyclophosphamide (ATC) In Breast
Cancer Patients With Positive Axillary Lymph
Nodes
NSABP B-33
Protocol
A Randomized,
Placebo-Controlled, double-Blind Trial
Evaluating the Effect of Exemestane in Clinical
Stage T1-3, N0-1, M0 Postmenopausal Breast
Cancer Patients Completing at Least Five Years
of Tamoxifen Therapy
NSABP B-34
Protocol
A Clinical
Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early-Stage Breast
Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No
Therapy
NSABP B-35
Protocol
A Clinical Trial Comparing Anastrozole with
Tamoxifen in Postmenopausal Patients with Ductal
Carcinoma in Situ (DCIS) Undergoing Lumpectomy
with Radiation Therapy
NSABP B-38
Protocol
A Phase
III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with
Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC);
Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD
AC-- P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC -- PG)
RTOG 98-04
Protocol
Phase III Trial of Tamoxifen Alone vs. Tamoxifen
Plus XRT for Good Risk Duct Carcinoma In-Situ (DCIS)
of the Female Breast
CTSU CALGB 49907
Protocol
A Randomized Trial of Adjuvant Chemotherapy With
Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil or
Doxorubicin and Cyclophosphamide Versus Capecitabine in Women 65 Years and Older
With Node Positive or High-Risk Node Negative Breast Cancer
NCCTG N0539
Protocol Phase
II Trial of Fulvestrant and Bevacizumab in Patients with Metastatic Breast
Cancer Previously Treated with an Aromatase Inhibitor
SWOG E1105
Protocol
(closed 10/28/2009) Randomized Phase III Double-Blind
Placebo-Controlled Trial of First-line
Chemotherapy and Trastuzumab with or without
Bevacizumab for Patients with HER-2/NEU
Over-expressing Metastatic Breast Cancer
NCCTG N083E Protocol
(11/12/09)
Phase II Safety Study of Docetaxel and
Carboplatin in Combination with Trastuzumab and
Lapatinib in Early Breast Cancer
NSABP B-42 Protocol
(1/6/2010)
Treatment Calendar A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal
Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI
in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
SWOG
S0307
Protocol Treatment
Calendar-Arm 1
TC-Arm 2
TC-Arm 3
(closing 2/1/10)
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast
Cancer
NSABP B-37 Protocol
Trt Calendar-Arm A TC-Arm B
(study closure 1/29/10)
A Randomized Clinical Trial of Adjuvant
Chemotherapy for Radically Resected Loco-regional Relapse of Breast Cancer
IBCSG 24-02
Protocol
Treatment
Calendar-Arm A
Arm B
Arm C A Phase III Trial Evaluating the Role of Ovarian
Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women
with Endocrine Responsive Breast Cancer
Colorectal
CTSU E5204
Protocol
(closure 4/29/09) Intergroup
Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and
Leucovorin versus Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for
Patients with Stage II or III Rectal Cancer Receiving Preoperative
Chemoradiation
NSABP
C-10
Protocol
(Closure 6/16/2009) A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6)
Chemotherapy plus Bevacizumab for Patients with Unresectable Stage IV Colon
Cancer and a Synchronous Asymptomatic Primary Tumor
CTSU E3201
Protocol
Intergroup Randomized Phase III Study of
Postoperative Irinotecan, 5-Fluorouracil, and
Leucovorin vs. Oxaliplatin, 5-Fluorouracil, and
Leucovorin vs. 5-Fluorouracil and Leucovorin for
Patients with Stage II or III Rectal Cancer
Receiving Either Preoperative Radiation and
5-Fluorouracil or Postoperative Radiation and
5-Fluorouracil
RTOG 98-11 Protocol
A Phase III Randomized Study of 5-FU,
Mitomycin-C and Radiotherapy vs. 5-FU, Cisplatin,
and Radiotherapy in Carcinoma of the Anal Canal
SWOG S0421 Protocol
Phase
III Study of Docetaxel and Atrasentan
Versus Docetaxel and Placebo for
Patients with Advanced Hormone
Refractory Prostate Cancer
NSABP C-08
Protocol
A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil, Leucovorin, and
Oxaliplatin Every Two Weeks with Bevacizumab to the Same Regimen Without
Bevacizumab for the Treatment of Patients with Resected Stages II and III
Carcinoma of the Colon
NSABP LTS-01
Protocol
Patient Reported Outcomes in Long-term Survivors with Colon and
Rectal Cancer
CTSU N0147
Protocol A Randomized Phase III
Trial of Irinotecan and/or Oxaliplatin Plus 5-Fluorouracil/Leucovorin with or
without Cetuximab (C225) after Curative
Resection for Patients with Stage III Colon Cancer
Gallbladder
GU
Bladder
SWOG 4B-95-1
Protocol
MVAC in Organ-Confined
Bladder Cancer Based on p53 Status
Renal
CTSU E8802
Protocol
Phase II Trial of Doxorubicin and Gemcitabine in
Metastatic Renal Cell Carcinoma with Sarcomatoid
Features
Gynecologic
CTSU GOG
0218
Protocol
A Phase III Trial of Carboplatin and Paclitaxil plus Placebo versus Carboplatin
and Paclitaxil plus Concurrent Bevacizumab followed by Placebo versus
Carboplatin and Paclitaxil plus Concurrent and Extended Bevacizumab in Women
with Newly Diagnosed, Previously Untreated Suboptimal Advanced Stage Epithelial
Ovarian and Primary Peritoneal Cancer
Head and
Neck
SWOG S0329
Protocol
Phase II Study of
Biweekly Gemcitabine and Paclitaxel Combination
in Patients with Recurrent or Metastatic
Squamous Cell Carcinoma of the Head and Neck
SWOG 0420
Protocol
Phase II Evaluation of BAY 43-9006 (NSC-724772)
in Patients with Recurrent or Metastatic Head
and Neck Cancer
CTSU E1302
Protocol
(closure
11/13/08)
Phase
III Randomized, Placebo-Controlled Trial of Docetaxel Versus Docetaxel Plus
ZD1839(Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients
with Recurrent or Metastatic Head and Neck Cancer
CTSU
GOG 0209 Protocol Randomized Phase III Trial of
Doxorubicin/Cisplatin/Paclitaxel and G-CSF vs. Carboplatin/Paclitaxel in Patients with
Stage III & IV or Recurrent Endometrial Cancer
Leukemia
SWOG S0301
Protocol A
Phase II Study of Induction with Daunorubicin,
Cytarabine, and Cyclosporine All by Continuous
IV Infusion for Previously Untreated Non-M3
Acute Myeloid Leukemia (AML) in Patients of Age
56 or Older
SWOG S0325
Protocol
(2/28/09)
A Phase IIb Study of Molecular Responses to
Imatinib at Standard or Increased Doses for Previously Untreated Patients with
Chronic Myelogenous Leukemia (CML) in Chronic Phase
Lung
RTOG R0623 Protocol
Phase II Trial of Combined Modality
Therapy with Growth Factor Support for Patients
with Limited Stage Small Cell Lung Cancer
NCCTG N0621
Protocol
(closed 8/26/2008) Phase II
Study of the c-SRC Inhibitor, AZD0530 after Four
Cycles of Cytoreductive Chemotherapy for
Patients with Extensive Stage Small Cell Lung
Carcinoma
SWOG
S0435
Protocol
Phase II Trial of BAY 43-9006 in Patients with
Platinum-Treated Extensive Stage Small Cell Lung Cancer
SWOG S0509
Protocol
A
Phase II Trial of Novel Oral Anti-angiogenic Agent AZD2171 in Malignant Pleural
Mesothelioma
NCCTG N0426
Protocol A
Phase II Study of Pemtrexed Disodium (Alimta) Plus Bevacizumab in Patients with
Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-line
Treatment)
CTSU E3598
Protocol
A Phase III Trial of Carboplatin, Paclitaxel and
Thoracic Radiotherapy, With or Without
Thalidomide in Patients with Stage III NSCLC
NCCTG N0623
Protocol
Phase II Study of GW786034 in Patients
with Malignant Pleural Mesothelioma
NCCTG N0528
Protocol A Randomized Phase II Study of Gemcitabine and
Carboplatin With or Without AZD2171 as First-Line Therapy in Advanced Non-Small
Cell Lung Cancer
SWOG
S0429
Protocol
( 08/15/09) A Pilot
(Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor
Risk Stage III Non-Small Cell Lung Cancer
Lymphoma
NCCTG N0682
Protocol
Treatment Calendar
(closure 4/19/10)A Phase II Clinical
Trial of Denileukin Diftitox in Combination with Rituximab in Previously
Untreated Follicular B-Cell Non-Hodgkin's Lymphoma
SWOG
S0520
Protocol
(closure 5/18/09)Phase II Study of PXD101 in
Relapsed and Refractory Aggressive B-Cell Lymphomas
NCCTG N0683
Protocol
A Phase II Study of Sunitinib
Malate for Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic
Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
CTSU E 4402
Protocol
A Randomized Phase III Trial
Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor
Burden Indolent Non-Hodgkin's Lymphoma
SWOG
S0515
Protocol
Phase II
Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
(CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell
NHL
SWOG S0016 Protocol
A Phase III Trial of CHOP vs. CHOP +
Rituximab vs. CHOP + Iodine 131 Labeled
Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly
Diagnosed Follicular Non-Hodgkin’s
Lymphoma (Closure Arm 1)
SWOG S0601 Protocol A
Phase II Study of Combination Rituximab-CHOP
and Bortezomib (Velcade) (R-CHOP-V)
Induction Therapy Followed by Bortezomib
Maintenance Therapy for Patients with
Newly Diagnosed Mantle Cell Lymphoma
SWOG S0349
Protocol
Standard Dose Cyclophosphamide,
Doxorubicin, Vincristine, Prednisone and
Rituximab, or Rituximab and G3139
Phosphorothioate (Anti-BCL-2 Antisense) Therapy
for Young Patients(<age60) with Advanced Stage Diffuse
Large B-Cell NHL of Low and Low-Intermediate IPI
Risk
SWOG
S0517
Protocol A
Phase II Trial of Suberoylanilide Hydroxamic Acid For Recurrent or Primary
Refractory Hodgkin's Lymphoma
CTSU E2496
Protocol Randomized
Phase III Trial of ABVD Versus Stanford V + Radiation Therapy in Locally
Extensive and Advanced Stage Hodgkin's Disease with 0-2 Risk Factors
NCCTG N038H
Protocol
(3/06/09) Phase II Study of CCI-779 in Combination
with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Melanoma
NCCTG N0675
Protocol
A Phase II
Study of Temozolomide and Everolimus (RAD-001) Therapy for Metastatic Melanoma
CTSU
E2603
Protocol
A
Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin,
Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in
Patients with Unresectable Locally Advanced or Stage IV Melanoma
SWOG E4697 Protocol
A
Randomized, Placebo-Controlled Phase III Trial
of Yeast Derived GM-CSF vs. Peptide Vaccination
vs. GM-CSF Plus Peptide Vaccination vs. Placebo
in Patients with No Evidence of Disease after
Complete Surgical Resection of Locally Advanced
and/or Stage IV Melanoma
SWOG S0008
Protocol
Phase III Trial of High Dose Interferon
Alpha-2b Versus Cisplatin, Vinblastine,
DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma
SWOG S0508
Protocol
A Phase II Trial of
Combination Thalidomide plus Temozolomide in Patients with Metastatic Malignant
Melanoma
SWOG S0438
Protocol Memo
(11/15/09)A
Randomized Phase II Trial of BAY 43-9006 (Sorafenib)
with Either CCI-779 (Temsirolimus) or R115777
(Tipifarnib) in Metastatic Melanoma
NCCTG N0775
Protocol
(12/23/09) A Randomized Phase II Trial of Temozolomide (TMZ) and
Avastin®
or ABI-007/
Carboplatin (CBDCA) and
Avastin®
in Patients with Unresectable Stage IV Malignant
Melanoma
Myeloma
SWOG
S0434
Protocol A
Phase II Trial of BAY 43-9006 (Sorafenib) in Patients with Relapsing or
Resistant Multiple Myeloma Previously Treated with Bortezomib
CTSU E4A03
Protocol
Randomized Phase III Study of CC-5013 plus Dexamethasone vs cc-5013 plus Low
Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone
Salvage Therapy for Non-Responders
CTSU E1A05
Protocol Randomized Phase III Trial of Consolidation
Therapy with Bortezomib (Velcade®) -
Lenalidomide (Revlimid®) - Dexamethasone (VRD)
versus Bortezomib (Velcade®) - Dexamethasone
(VD) for Patients with Multiple Myeloma Who
Have Completed a Dexamethasone-Based
Induction Regimen
Ovarian
GOG 0182 Protocol
A Phase III Randomized Trial of Paclitaxel
and Carboplatin Versus Triplet or Sequential
Doublet Combinations in Patients with Epithelial
Ovarian or Primary Peritoneal Carcinoma
Pancreatic
CTSU E6201
Protocol
A Phase III Randomized
Study of Gemcitabine (fixed-dose rate infusion)
and Oxaliplatin (NSC #266046) vs. Gemcitabine
(fixed-dose rate infusion) vs. Gemcitabine
(30-minute infusion) in Pancreatic Carcinoma
NCCTG N034A Protocol Phase
II Study of Bevacizumab, Gemcitabine,
Oxaliplatin in Patients with Metastatic
Pancreatic Cancer
CALGB 80303 Protocol
A Randomized Phase
III Trial of Gemcitabine plus Bevacizumab vs. Gemcitabine plus Placebo in
Patients with Advanced Pancreatic Cancer
Prostate
SWOG 9921
Protocol
Adjuvant Androgen Deprivation vs. Mitoxantrone
Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer
Patients Following Radical Prostatectomy
(Press Release)
JPR.7
Protocol
A
Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen
Suppression for Patients with Prostate-Specific-Antigen Progression in the
Clinical Absence of Distant Metastases Following Radiotherapy for Prostate
Cancer
C90401
Protocol
A Randomized Double-blinded
Placebo-controlled Phase III Trial Comparing
Docetaxel and Prednisone with and without
Bevacizumab in Men with Hormone-refractory
Prostate Cancer
SWOG S0354
Protocol
A
Phase II Study of CTNO 328, A Monoclonal
Antibody Against Interleukin-6 (IL-6), in
Patients with Hormone Refractory Prostate Cancer
CTSU CALGB 90401
Protocol
(Closing 12/21/07)
A Randomized, Double-Blinded. Placebo-Controlled
Phase III Trial Comparing Docetaxel and
Prednisone With and Without Bevacizumab in Men
with Hormone Refractory Prostate Cancer
CTSU RTOG 0521
Protocol A Phase III Protocol of
Androgen Suppression (AS) and Radiotherapy (RT) vs AS and RT Followed by
Chemotherapy with Doxetaxel and Prednisone for Localized High-Risk Prostate
Cancer
SWOG S0421
Protocol (closing
5/1/10) Phase III Study of
Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced
Hormone Refractory Prostate Cancer
Renal
CTSU CALGB 90206
Protocol
A Randomized Phase III Trial of
Interferon Alfa-2B or Interferon Alfa-2B Plus
Bevacizumab in Patients with Advanced Renal
Carcinoma
Stomach/Esophageal
CTSU
C80101 Protocol
A Phase III
Intergroup Trial of Adjuvant Chemoradiation after Resection of Gastric or
Gastroesophageal Adenocarcinoma
SWOG S0413
Protocol
Phase II Study of GW572016 as First Line Therapy
in Patients with Advanced or Metastatic Gastric
Cancer
SWOG S0414
Protocol
Cetuximab Plus
Cisplatin Irinotecan and Thoracic Radiotherapy for Locally Advanced
(Non-Metastatic), Clinically Unresectable Esophageal Cancer: A Phase II
Trial with Molecular Correlates
SWOG S0356
Protocol
Oxaliplatin Plus Protracted Infusion
5-Fluorouracil and Radiation for Potentially
Curable Esophageal Cancer: A Phase II Trial with
Molecular Correlates
Cancer Control
NCCTG N03CC
Protocol
A Randomized, Controlled, Open-label Trial of Empiric
Prophylactic vs Delayed Use of Zoledronic Acid for Prevention of Bone Loss in
Postmenopausal Women with Breast Cancer Initiating Therapy with Letrozole after
Tamoxifen
RTOG R0518
Protocol (Closing
1/30/09) Phase
III, Double-Blind, Placebo-Controlled Study to
Evaluate the Efficacy of Zometa for the
Prevention of Osteoporosis and Associated
Fractures in Patients Receiving Radiation
Therapy and Long-term LHRH Agonists for
High-Grade and/or Locally Advanced Prostate
Cancer
SWOG
E5597
Protocol
MD letter
Patient Letter - on Patient Letter
-off
Phase III Chemoprevention Trial of Selenium
Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer
|
